Trial · NCT05603104
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
NCT05603104, Phase 3, Terminated, Dr. Inge Winter
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure. Trials, record NCT05603104. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05603104
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
- NCT number
- NCT05603104
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 1 participants, actual
- Lead sponsor
- Dr. Inge Winter
- Conditions
- Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression
- Interventions
Clozapine, Esketamine Nasal Product, Escitalopram, Sertraline, Venlafaxine, Lithium, Valproate acid, Quetiapine, Second-line Antidepressants, Second-line Antipsychotics, Ketamine Hydrochloride, Esketamine hydrochloride, Bupropion
- First posted
- 2022-11-02
- Last updated
- 2026-11-05
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in symptom severity | 6 weeks | Change in symptom severity total score from baseline (visit 2) to end of treatment (visit 4). For Schizophrenia, this is measured using the Positive And Negative Syndrome Scale. For Major Depressive Disorder and Bipolar Depression, Montgomery Åsberg Depression Rating Scale is applied. |
| Secondary | All study samples: to compare changes in the severity and improvement | 6 weeks | All study samples: to compare changes in the severity and improvement sub-scores of the Clinical Global Impression Scale between the two treatment arms over the six weeks treatment period (visit 2 versus visit 4). |
| Secondary | All study samples: to compare changes in the levels of depression and anxiety | 6 weeks | All study samples: to compare changes in the levels of depression and anxiety as assessed with the Hospital Anxiety and Depression Scale bbetween the two treatment arms over the six weeks treatment period (visit 2 versus visit 4). |
| Secondary | All study samples: to compare changes in cognitive performance #1 | 6 weeks | All study samples: to compare changes in cognitive performance as measured through the Trail Making Test between the two treatment arms over the six weeks treatment period (visit 2 versus visit 4). |
| Secondary | All study samples: to compare changes in cognitive performance #2 | 6 weeks | All study samples: to compare changes in cognitive performance as measured through the Digit Symbol Substitution Test between the two treatment arms over four weeks (Major Depressive Disorder Group)/six weeks (Schizophrenia/Bipolar Depression groups) treatment period (visit 2 versus visit 4). |
| Secondary | All study samples: to compare changes in cognitive performance #3 | 6 weeks | All study samples: to compare changes in cognitive performance as measured through the Rey Auditory Verbal Learning Test between the two treatment arms over the six weeks treatment period (visit 2 versus visit 4). |
| Secondary | All study samples: to compare changes in cognitive performance #4 | 6 weeks | All study samples: to compare changes in cognitive performance as measured through the Perceived Deficits Questionnaire between the two treatment arms over the six weeks treatment period (visit 2 versus visit 4). |
| Secondary | All study samples: to compare changes in functioning measure #1 | 6 weeks | All study samples: to compare changes in functioning measure (Leuven Afective and Pleasure Scale) between the two treatment arms over the four weeks (Major Depressive Disorder Group)/six weeks (Schizophrenia/Bipolar Depression groups) treatment period (visit 2 versus visit 4). |
| Secondary | All study samples: to compare changes in functioning measure #2 | 6 weeks | All study samples: to compare changes in functioning measure (Sheehan Disability Scale) between the two treatment arms over the four weeks (Major Depressive Disorder Group)/six weeks (Schizophrenia/Bipolar Depression groups) treatment period (visit 2 versus visit 4). |
| Secondary | All study samples: to compare changes in quality of life #1 | 6 weeks | All study samples: to compare changes in quality of life (Quality of Life Enjoyment and Satisfaction Questionnaire Short Form) between the two treatment arms over the six weeks treatment period (visit 2 versus visit 4). |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 41401709 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Symbol Coding | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05603104
GET https://conductscience.org/api/trials/v1/NCT05603104/registered